{
    "clinical_study": {
        "@rank": "146178", 
        "arm_group": [
            {
                "arm_group_label": "Denosumab 60mg subcutaneous injection", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit."
            }, 
            {
                "arm_group_label": "Alendronate 70mg weekly x 8 weeks", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis\n      medications when combined with teriparatide."
        }, 
        "brief_title": "Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Postmenopausal Osteoporosis", 
        "condition_browse": {
            "mesh_term": [
                "Bone Resorption", 
                "Osteoporosis", 
                "Osteoporosis, Postmenopausal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Must satisfy A and B and C below:\n\n        A. Women aged 45+\n\n        B. Postmenopausal\n\n        C. Osteoporotic with high risk of fracture\n\n        Exclusion Criteria:\n\n          -  History of significant hepatic, renal, cardiovascular, malignant disease, or\n             conditions with impaired immune system\n\n          -  Current alcohol or substance abuse\n\n          -  Major psychiatric disorders\n\n          -  Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia\n\n          -  Known congenital or acquired bone disease other than osteoporosis\n\n          -  Current use or past use in the past 12 months of oral bisphosphonates\n\n          -  Current use or use in the past 3 months of estrogens, selective estrogen receptor\n             modulators, or calcitonin\n\n          -  Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months\n\n          -  Any current or previous use of strontium or intravenous bisphosphonates\n\n          -  Sensitivity to cell-derived drug products or teriparatide\n\n          -  Extensive dental work involving dental extraction or dental implant within the past 2\n             months or in the upcoming 2 months\n\n          -  Inability to sit upright for 30 minutes\n\n          -  Esophageal abnormalities"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750086", 
            "org_study_id": "2012P001956"
        }, 
        "intervention": {
            "arm_group_label": [
                "Denosumab 60mg subcutaneous injection", 
                "Alendronate 70mg weekly x 8 weeks"
            ], 
            "intervention_name": "Teriparatide 40-mcg subcutaneous injection", 
            "intervention_type": "Drug", 
            "other_name": "Forteo\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Diphosphonates", 
                "Alendronate", 
                "Teriparatide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "osteoporosis", 
            "postmenopausal", 
            "denosumab", 
            "teriparatide", 
            "alendronate", 
            "Forteo\u00ae", 
            "Prolia\u00ae"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "contact": {
                "last_name": "Joy Tsai, MD", 
                "phone": "617-726-4650"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Benjamin Z Leder, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption", 
        "overall_contact": {
            "email": "bzleder@partners.org", 
            "last_name": "Benjamin Z Leder, MD", 
            "phone": "617-724-2039"
        }, 
        "overall_contact_backup": {
            "email": "jntsai@partners.org", 
            "last_name": "Joy N Tsai, MD", 
            "phone": "617-726-4650"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Bone turnover marker (blood sample)", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "reference": [
            {
                "PMID": "20814967", 
                "citation": "Cosman F, Eriksen EF, Recknor C, Miller PD, Gua\u00f1abens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238."
            }, 
            {
                "PMID": "14500805", 
                "citation": "Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-26. Epub 2003 Sep 20."
            }, 
            {
                "PMID": "16093465", 
                "citation": "Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005 Aug 11;353(6):566-75."
            }, 
            {
                "PMID": "11564687", 
                "citation": "Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001 Oct;142(10):4295-304."
            }, 
            {
                "PMID": "20164296", 
                "citation": "Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45. doi: 10.1210/jc.2009-1703. Epub 2010 Feb 17."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750086"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Benjamin Leder, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}